OBJECTIVE: To identify predictors of mortality in patients initiating antiretroviral therapy (ART) in Durban, South Africa. DESIGN: We conducted a retrospective cohort study analyzing data on patients who presented to McCord Hospital, Durban, and started ART between 1 January 1999 and 29 February 2004. We performed univariate and multivariate analysis and constructed Kaplan-Meier curves to assess predictors. RESULTS: Three hundred and nine patients were included. Forty-nine (16%) had died by the conclusion of the study. In univariate analysis, the strongest predictors of mortality were a CD4 cell count<50/microl (hazard ratio (HR) 3.70, 95% confidence interval (CI) 1.96-7.14), a haemoglobin concentration<or=8 g/dl (HR 1.23, 95% CI 1.08-1.40), a history of oral candidiasis (HR 3.17, 95% CI 1.70-5.87) and a history of cryptococcal meningitis (HR 2.76, 95% CI 1.80-19.2). A CD4 cell count<50/microl (HR 3.08, 95% CI 1.54-5.88) and a history of oral candidiasis (HR 2.58, 95% CI 1.37-4.88) remained significant in multivariate analysis. A history of tuberculosis was not a significant predictor of mortality. CONCLUSIONS: Simple clinical and laboratory data independently predict mortality and allow for risk stratification in patients initiating ART in South Africa. Interventions enabling patients to be identified before they develop these clinical markers and earlier initiation of ART will help to ensure maximum benefits of therapy.
OBJECTIVE: To identify predictors of mortality in patients initiating antiretroviral therapy (ART) in Durban, South Africa. DESIGN: We conducted a retrospective cohort study analyzing data on patients who presented to McCord Hospital, Durban, and started ART between 1 January 1999 and 29 February 2004. We performed univariate and multivariate analysis and constructed Kaplan-Meier curves to assess predictors. RESULTS: Three hundred and nine patients were included. Forty-nine (16%) had died by the conclusion of the study. In univariate analysis, the strongest predictors of mortality were a CD4 cell count<50/microl (hazard ratio (HR) 3.70, 95% confidence interval (CI) 1.96-7.14), a haemoglobin concentration<or=8 g/dl (HR 1.23, 95% CI 1.08-1.40), a history of oral candidiasis (HR 3.17, 95% CI 1.70-5.87) and a history of cryptococcal meningitis (HR 2.76, 95% CI 1.80-19.2). A CD4 cell count<50/microl (HR 3.08, 95% CI 1.54-5.88) and a history of oral candidiasis (HR 2.58, 95% CI 1.37-4.88) remained significant in multivariate analysis. A history of tuberculosis was not a significant predictor of mortality. CONCLUSIONS: Simple clinical and laboratory data independently predict mortality and allow for risk stratification in patients initiating ART in South Africa. Interventions enabling patients to be identified before they develop these clinical markers and earlier initiation of ART will help to ensure maximum benefits of therapy.
Authors: Alexander J Frater; David T Dunn; Alison J Beardall; Koya Ariyoshi; John R Clarke; Myra O McClure; Jonathan N Weber Journal: AIDS Date: 2002-05-24 Impact factor: 4.177
Authors: Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Spencer Lieb; Robert G Brooks; Richard S Hopkins; Dan Thompson; Landis K Crockett; Thomas Liberti; Asim A Jani; Jeffrey P Nadler; Vikas M Virkud; Karen C West; Gayle McLaughlin Journal: J Acquir Immune Defic Syndr Date: 2002-07-01 Impact factor: 3.731
Authors: Roxanna Farinpour; Eric N Miller; Paul Satz; Ola A Selnes; Bruce A Cohen; James T Becker; Richard L Skolasky; Barbara R Visscher Journal: J Clin Exp Neuropsychol Date: 2003-08 Impact factor: 2.475
Authors: Paula Braitstein; Martin W G Brinkhof; François Dabis; Mauro Schechter; Andrew Boulle; Paolo Miotti; Robin Wood; Christian Laurent; Eduardo Sprinz; Catherine Seyler; David R Bangsberg; Eric Balestre; Jonathan A C Sterne; Margaret May; Matthias Egger Journal: Lancet Date: 2006-03-11 Impact factor: 79.321
Authors: Manuel Koller; Geoffrey Fatti; Benjamin H Chi; Olivia Keiser; Christopher J Hoffmann; Robin Wood; Hans Prozesky; Kathryn Stinson; Janet Giddy; Portia Mutevedzi; Matthew P Fox; Matthew Law; Andrew Boulle; Matthias Egger Journal: J Acquir Immune Defic Syndr Date: 2015-11-01 Impact factor: 3.731
Authors: Margaret May; Andrew Boulle; Sam Phiri; Eugene Messou; Landon Myer; Robin Wood; Olivia Keiser; Jonathan A C Sterne; Francois Dabis; Matthias Egger Journal: Lancet Date: 2010-07-15 Impact factor: 79.321
Authors: Elizabeth C Russell; Salome Charalambous; Lindiwe Pemba; Gavin J Churchyard; Alison D Grant; Katherine Fielding Journal: BMC Public Health Date: 2010-07-23 Impact factor: 3.295
Authors: Morna Cornell; Michael Schomaker; Daniela Belen Garone; Janet Giddy; Christopher J Hoffmann; Richard Lessells; Mhairi Maskew; Hans Prozesky; Robin Wood; Leigh F Johnson; Matthias Egger; Andrew Boulle; Landon Myer Journal: PLoS Med Date: 2012-09-04 Impact factor: 11.069